Clinical Trial

A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated January 7, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this clinical study is to evaluate the safety and immunogenicity of receiving two doses of recombinant herpes zoster vaccine (CHO cells) (RHZV) in healthy individuals aged 40 years and above. This study will be conducted in 2 substudies: Substudy A (Phase I) and Substudy B (Phase Ⅱ).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-10.
Status change: Not Yet Recruiting → Recruiting 2026-01-05
Trial Details
NCT Number NCT06932523
Lead Sponsor Shanghai Institute Of Biological Products
Conditions Herpes Zoster (HZ)
Enrollment 645 participants
Start Date 2025-04-04
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-07